The strong Q2 beat and potential guidance raise signal accelerating commercial adoption of Amtagvi. Traders should watch for the formal guidance update in Q3 and upcoming ESMO data presentations (Oct 23-27) for lifileucel in sarcomas and frontline melanoma, which could be additional catalysts.
Drugs in focus
IOVA drug pipeline →Amtagvi
● Neutral Named in this 8-K- Impact
- Phase
- Approved (accelerated approval)
- Time to market
- Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
- Next catalyst
- BLA filing · 2027
What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $6.21entry
- T+1 · 3mo ago +2.09%α +1.48% · $6.34
- T+5 · 3mo ago +4.99%α +3.78% · $6.52
- T+20 · 3mo ago +40.10%α +39.50% · $8.70
- T+60 · 18d ago +36.55%α +38.22% · $8.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Iovance reported record Q2 2026 revenue of ~$99.3M, a 66% YoY increase, driven by U.S. Amtagvi revenue of ~$91M. Gross margin improved to 56%, and the net loss narrowed to -$0.11/share from -$0.33/share YoY. The company is reviewing its FY26 revenue guidance of $350M-$370M for a potential raise, while advancing its pipeline with FDA Fast Track Designation for lifileucel in soft tissue sarcomas.
Key Financial Metrics
Key Facts
- Total product revenue of ~$99.3M, up 66% YoY from ~$59.95M in Q2 2025.
- U.S. Amtagvi revenue reached ~$91M, up 40% from Q4 2025.
- Gross margin improved to 56% from 41% in Q1 2026.
- Net loss per share narrowed to -$0.11 from -$0.33 YoY, beating consensus of -$0.13.
- Company reviewing FY26 revenue guidance of $350M-$370M for a potential raise.
- FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (UPS and DDLPS).
- Cash position of ~$304M expected to fund operations into 2H28.
Financial Impact
Record quarterly revenue of $99.3M, 66% YoY growth; net loss narrowed by $64.3M YoY to $47.3M.
Risk Factors
- Revenue growth dependent on continued Amtagvi adoption and ATC network expansion.
- Company remains unprofitable with operating losses; path to profitability uncertain.
- Clinical pipeline risks: trial enrollment, regulatory approvals, and competition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-091619 |
| Document: tm2622322d1_8k.htm | 0001104659-26-091619 |
| Document: 0001104659-26-091619-index-headers.html | 0001104659-26-091619 |
| Document: 0001104659-26-091619-index.html | 0001104659-26-091619 |
| Document: 0001104659-26-091619.txt | 0001104659-26-091619 |
| 8-K Data (Synthetic) | 0001104659-26-091619 |
Track record
21 reports on IOVA
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
- Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
- Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers